Synaffix BV, a Lonza company, is a biotech company that has established a proprietary, clinical-stage technology platform that enables best-in-class antibody-drug conjugates (ADCs) in terms of safety and efficacy. Our technology out-licensing business has already translated into 5 ADCs entering the clinic, more than 20 distinct ADC programs being developed across our 13 partners and over $7.6Bn in total potential value from our out-licensing deals. Our partners include top-tier biotech and pharma companies such as ADC Therapeutics, Mersana Therapeutics, Janssen, Shanghai Miracogen, Innovent Biologics, ProfoundBio, Kyowa Kirin, Genmab, Macrogenics, Emergence Therapeutics (recently acquired by Lilly), Hummingbird Bioscience, Amgen and Chong Kun Dang Pharm. Synaffix offers a consolidated ADC platform technology that enables any company with an antibody to develop a proprietary, best-in-class ADC and our patent portfolio provides granted protection of any resulting Products through at least 2035. Rather than developing a pipeline of our own drugs, the business model of Synaffix is technology out-licensing where we regularly engage in discovery research collaborations with companies that are interested in developing highly competitive ADC Products using our proprietary technology.